- Global Pharma News & Resources

How Many Cardiac Surgeries Are Performed Each Year? – New Study by iData Research


According to a new cardiac surgery market study by iData Research, the number of cardiac surgeries exceeds 900,000 procedures each year in the United States. The US Cardiac surgery market is growing rapidly driven by the growth of many underlying procedures.
  • Author Name: iData Research
Editor: Mya Hastie Last Updated: 09-Mar-2021

The number of cardiac surgery procedures commonly includes:

• Coronary Artery Bypass Grafting (CABG)
• Transcatheter Aortic Valve Replacements (TAVR)
• Surgical Heart Valve Replacements
• Annuloplasty Repairs
• Transcatheter Mitral Valve Repairs (TMVR)
• Balloon Valvuloplasties
• Transmyocardial Revascularizations
• Intra-Aortic Balloon Counterpulsation
• Donor Heart Transplants


In the US cardiac surgery market, the largest portion of the procedures comes from coronary artery bypass graft (CABG) procedures. Despite being the most common type of procedure, CABG procedures are declining as more effective alternatives are growing. Most of the CABG procedures are done via the on-pump method (ONCAB), where the patient’s heart is stopped and the circulatory system is temporarily maintained. A smaller portion of the CABG procedures is performed via the off-pump technique (OPCAB), where the surgery is performed directly on the beating heart.

The second-largest type of procedure performed in the US cardiac surgery market is the surgical heart valve replacement (SHVR) procedure. In recent years, surgical heart valve replacements have experienced a significant decline in procedures due to the development of minimally invasive solutions, such as transcatheter heart valve replacement (THVR) devices. The SHVR procedure can be performed using a tissue or mechanical heart, and the decline in tissue valve procedures is expected to be more significant than the decline in mechanical heart valve procedures.

Partially at the expense of SHVR procedures, the THVR procedures are expected to grow rapidly, which encompasses the growth of both transcatheter aortic valve (TAVR) and pulmonary valve (TPVR) replacement procedures. This growth can be primarily attributed to a recent FDA approval expanding the indications for TAVR to include low-risk patients. However, the growth in THVR procedural volume will be limited by the lack of clinical data on long-term patient outcomes, as well as the complexity and risk of the TAVR and TPVR procedures.

The fastest-growing cardiac surgery in the US by the growth in numbers is Transcatheter Mitral Valve Repair (TMVr). The potential for TMVr procedures is derived from the incidence of significant mitral regurgitation (MR), which affects approximately 1% of the population in the United States. Abbott received FDA approval to expand the indication for their TMVr deviceMitraclip™, to patients with clinically significant secondary mitral regurgitation. Similar to TAVR procedures, this will greatly expand the cohort of patients and propel the growth in TMVr procedures.


Read at:

According to the recent market study by iData Research, the total cardiac surgery procedure volume is expected to continue growing at about 5% per year, reaching over 1.3 million annual procedures in 2026. While the COVID19 pandemic resulted in a significant decline in cardiac surgery procedures in 2020, the procedure volumes are expected to fully recover in late 2021.